PCM
KRYS icon

Prelude Capital Management’s Krystal Biotech KRYS Stock Holding History

Prelude Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,032
Closed -$254K – 1424
2025
Q4 		$254K Buy
+1,032
New +$217K 0.02% 877
2024
Q2 		– Sell
-3,403
Closed -$605K – 1370
2024
Q1 		$605K Buy
+3,403
New +$473K 0.03% 554
2018
Q3 		– Sell
-100
Closed -$1K – 1887
2018
Q2 		$1K Buy
+100
New +$1.13K ﹤0.01% 1609

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's KRYS Position: Q1 2026 in Review

Prelude Capital Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,032 shares — an estimated $254K sold.

Prelude Capital Management first reported a position in KRYS in Q2 2018 and held it in 3 quarters. The position peaked at $605K in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Prelude Capital Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 1,032 Krystal Biotech shares in Q1 2026, an estimated $254K.
  • Prelude Capital Management first reported a position in Krystal Biotech in Q2 2018 and held it in 3 quarters.
  • Prelude Capital Management's Krystal Biotech position peaked at $605K in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.